Abstract
Sotagliflozin (SOTA) is a dual SGLT1 and SGLT2 inhibitor in development as an adjunct to insulin in T1D.
Full Text
Sign-in/Register to access full text options
Published version (Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have